ACUTA CAPITAL PARTNERS, LLC — 13F Holdings & Portfolio
CIK 1582844 · latest 13F-HR filed 2026-08-14
ACUTA CAPITAL PARTNERS, LLC manages $143.5M in 13F-reported U.S. long-equity assets across 23 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PRAX (19.32%), WHWK (14.96%), TNGX (8.52%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions and exited 8; 10 existing positions rose in reported value and 6 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 73.7%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Jun 30, 2026.
SUITE 515
REDWOOD CITY, CA 94065
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| DALAL, ANUPAM, AKSHAY Control | MANAGING MEMBER, CHIEF INVESTMENT OFFICER since Dec 2017 | 75% or more | Individual |
| DALAL, ANUPAM, AKSHAY Control | MANAGING MEMBER, CHIEF INVESTMENT OFFICER since Dec 2017 | 75% or more | Individual |
| SMITH, SCOTT, RANDALL Control | CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER since Aug 2020 | Less than 5% | Individual |
| SMITH, SCOTT, RANDALL Control | CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER since Aug 2020 | Less than 5% | Individual |
| THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 | MEMBER since Aug 2018 | 10–25% | Domestic Entity |
| THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 | MEMBER since Aug 2018 | 10–25% | Domestic Entity |
| LAY, GRACE, VIVIAN Control Indirect owner via THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 | BENEFICIARY/TRUSTEE since Aug 2018 | General partner, trustee or manager | Individual |
| LAY, GRACE, VIVIAN Control Indirect owner via THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 | BENEFICIARY/TRUSTEE since Aug 2018 | General partner, trustee or manager | Individual |
| YU, MANFRED, HSIAO-WEI Control Indirect owner via THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 | TRUSTEE since Aug 2018 | General partner, trustee or manager | Individual |
| YU, MANFRED, HSIAO-WEI Control Indirect owner via THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 | TRUSTEE since Aug 2018 | General partner, trustee or manager | Individual |
Ownership & leadership changes · 6 filings with changes since Apr 1, 2015
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedLAY, GRACE, VIVIAN · indirect via THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007: ownership 75% or more → General partner, trustee or manager
- No longer listedLAY, GRACE, VIVIAN · TRUSTEE OF THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 · Less than 5% · control person · listed since Aug 2018
- No longer listedYU, MANFRED, HSIAO-WEI · MANAGER, MANAGING DIRECTOR, CCO, COO, TRUSTEE OF THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 · Less than 5% · control person · listed since Jul 2014
- AddedSMITH, SCOTT, RANDALL · CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedDALAL, ANUPAM, AKSHAY · title CHIEF INVESTMENT OFFICER → MANAGING MEMBER, CHIEF INVESTMENT OFFICER; ownership Less than 5% → 75% or more
- ChangedTHE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 · title OWNER → MEMBER; ownership 75% or more → 10–25%; no longer a control person
- AddedLAY, GRACE, VIVIAN · TRUSTEE OF THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 · Less than 5% · control person
- ChangedDALAL, ANUPAM, AKSHAY · now a control person
- ChangedLAY, GRACE, VIVIAN · indirect via THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007: title TRUSTEE → BENEFICIARY/TRUSTEE; ownership General partner, trustee or manager → 75% or more
- ChangedYU, MANFRED, HSIAO-WEI · title MANAGER, MANAGING DIRECTOR, CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER → MANAGER, MANAGING DIRECTOR, CCO, COO, TRUSTEE OF THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007
- No longer listedLIN, RICHARD, YU-TSANG · MANAGING MEMBER · 75% or more · control person · listed since Jul 2011
- AddedLAY, GRACE, VIVIAN · TRUSTEE · General partner, trustee or manager · indirect via THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 · control person
- AddedTHE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 · OWNER · 75% or more · control person
- AddedYU, MANFRED, HSIAO-WEI · TRUSTEE · General partner, trustee or manager · indirect via THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 · control person
- ChangedYU, MANFRED, HSIAO-WEI · title CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER → MANAGER, MANAGING DIRECTOR, CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER
- AddedDALAL, ANUPAM, AKSHAY · CHIEF INVESTMENT OFFICER · Less than 5%
- ChangedLIN, RICHARD, YU-TSANG · title MANAGING MEMBER AND CHIEF INVESTMENT OFFICER → MANAGING MEMBER
- ChangedLIN, RICHARD, YU-TSANG · title MANAGING MEMBER → MANAGING MEMBER AND CHIEF INVESTMENT OFFICER
- ListedLIN, RICHARD, YU-TSANG · MANAGING MEMBER · 75% or more · control person
- ListedYU, MANFRED, HSIAO-WEI · CHIEF COMPLIANCE OFFICER AND CHIEF OPERATING OFFICER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- WHITEHAWK THERAPEUTICS INC$9.7M +82.4%
- TANGO THERAPEUTICS INC$3.0M +32.2%
- DESIGN THERAPEUTICS INC$2.5M +163.4%
- AVALO THERAPEUTICS INC$2.5M +279.2%
- SUTRO BIOPHARMA INC$2.3M +33.7%
Top Trims
- COMPASS THERAPEUTICS INC-$3.2M -71.0%
- BRIGHT MINDS BIOSCIENCES INC-$1.7M -20.3%
- ERASCA INC-$878.6K -15.3%
- SURROZEN INC-$535.4K -10.6%
- MINERVA NEUROSCIENCES-$337.0K -7.9%
New Positions
- ARRIVENT BIOPHARMA INC$7.6M
- 4D MOLECULAR THERAPEUTICS INC$6.8M
- AVALYN PHARMA INC$3.8M
- ARTIVA BIOTHERAPEUTICS INC$2.5M
- CONTINEUM THERAPEUTICS INC-A$1.0M
Exited Positions
- TERNS PHARMACEUTICALS INC$26.1M
- OCULIS HOLDING AG$2.6M
- REVOLUTION MEDICINES INC$2.5M
- 4D MOLECULAR THERAPEUTICS INC$2.3M
- IDEAYA BIOSCIENCES INC$1.6M
ACUTA CAPITAL PARTNERS, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $27.7M | 19.32% | 82,796 | SH |
| 2 | WHITEHAWK THERAPEUTICS INC | WHWK | 00032Q104 | $21.5M | 14.96% | 4,685,912 | SH |
| 3 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $12.2M | 8.52% | 390,949 | SH |
| 4 | SUTRO BIOPHARMA INC | STRO | 869367201 | $9.0M | 6.25% | 270,251 | SH |
| 5 | ARRIVENT BIOPHARMA INC | AVBP | 04272N102 | $7.6M | 5.29% | 218,694 | SH |
| 6 | 4D MOLECULAR THERAPEUTICS INC | FDMT | 35104E100 | $6.8M | 4.71% | 507,801 | SH |
| 7 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $6.5M | 4.54% | 92,745 | SH |
| 8 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $5.2M | 3.64% | 532,481 | SH |
| 9 | ERASCA INC | ERAS | 29479A108 | $4.9M | 3.39% | 265,199 | SH |
| 10 | SURROZEN INC | SRZN | 86889P208 | $4.5M | 3.14% | 173,395 | SH |
| 11 | ARGEN SE - ADR | ARGX | 04016X101 | $4.4M | 3.04% | 4,705 | SH |
| 12 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $4.2M | 2.93% | 215,652 | SH |
| 13 | DESIGN THERAPEUTICS INC | DSGN | 25056L103 | $4.1M | 2.85% | 282,564 | SH |
| 14 | MINERVA NEUROSCIENCES | NERV | 603380205 | $3.9M | 2.74% | 709,500 | SH |
| 15 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $3.8M | 2.67% | 561,808 | SH |
| 16 | AVALYN PHARMA INC | AVLN | 05348Y105 | $3.8M | 2.64% | 115,000 | SH |
| 17 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $3.4M | 2.40% | 186,308 | SH |
| 18 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $3.0M | 2.10% | 168,115 | SH |
| 19 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $2.5M | 1.76% | 260,416 | SH |
| 20 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $1.3M | 0.91% | 595,213 | SH |
| 21 | UNITED THERAPEUTICS CORP | UTHR | 91307C102 | $1.2M | 0.84% | 2,224 | SH |
| 22 | CONTINEUM THERAPEUTICS INC-A | CTNM | 21217B100 | $1.0M | 0.72% | 63,095 | SH |
| 23 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $938.6K | 0.65% | 28,919 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $143.5M | 23 | 0001104659-26-096822 |
| 2026-03-31 | 2026-05-15 | $141.8M | 27 | 0001104659-26-062163 |
| 2025-12-31 | 2026-02-17 | $147.3M | 30 | 0001104659-26-016119 |
| 2025-09-30 | 2025-11-14 | $96.8M | 28 | 0001104659-25-112378 |
SUITE 515
REDWOOD CITY, CA 94065